ERBB2 and breast cancer: In this trial, 258 postmenopausal patients with metastatic HR+/HER2+ breast cancer who did not receive prior systemic chemotherapy for metastatic disease were randomized to receive a combination of trastuzumab and an AI (anastrozole or letrozole), or trastuzumab plus pertuzumab and an AI.